Pre-market: 9678.HK Unisound AI (HKSE) at HK$344.80 on 19 Feb 2026: AI test ahead

We see 9678.HK stock trading pre-market at HK$344.80 on 19 Feb 2026, down HK$5.60 or -1.60% from the prior close. This move follows a recent pullback from the 50-day average HK$355.23 and far below the 200-day average HK$505.64. Volume is light at 91,720 shares versus an average 514,465. We focus on valuation, technical signals, and Meyka AI’s model forecast to judge whether Unisound AI Technology Co Ltd. can re-accelerate in Hong Kong’s technology sector.

Market snapshot: 9678.HK stock pre-market on 19 Feb 2026

Unisound AI Technology Co Ltd. (9678.HK) listed on the HKSE trades in HKD and shows a market cap of HKD 24,467,334,870.00. The stock opened at HK$350.40, with a day low of HK$300.00 and day high of HK$353.00.

Trading today is light with 91,720 shares so far, or relative volume 0.18, compared with a 50-day average volume of 514,465. The stock remains volatile year-to-date and sits between a 52-week low of HK$198.00 and high of HK$879.00.

Valuation and fundamentals: 9678.HK stock earnings and metrics

Unisound reports an EPS of -7.88 and a trailing PE of -43.76, reflecting recent operating losses. The negative PE contrasts with the Technology sector average PE of 35.37, underscoring higher risk and growth expectations for peers.

Shares outstanding total 70,960,948, and the 50-day price average is HK$355.234 against the 200-day average HK$505.64075. These metrics indicate a stock still in early post-IPO discovery and with wide valuation dispersion.

Technical setup and trading levels for 9678.HK stock

Technical indicators show mixed momentum for 9678.HK stock. The RSI sits at 52.72, ADX at 32.09 signaling a strong trend, and MACD histogram at 8.69 shows short-term bullish momentum.

Key support is near the day low at HK$300.00 and resistance clusters at the 50-day average HK$355.23 and the 200-day average HK$505.64. Traders should watch a break above HK$360.00 for short-term confirmation.

Meyka AI grade and forecast for 9678.HK stock

Meyka AI rates 9678.HK with a score out of 100: the model returns a score of 63.67, grade B, suggestion HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus.

Meyka AI’s forecast model projects a monthly price of HK$533.54, versus the current price HK$344.80, implying an upside of 54.78%. Forecasts are model-based projections and not guarantees. For live news and quote context see Investing.com coverage and the platform benchmark tools Investing.com benchmark.

Risks and opportunities for 9678.HK stock investors

Opportunity: Unisound’s UniBrain LLM platform targets healthcare and smart life, areas with high AI adoption potential. The stock benefits from strong sector interest in Hong Kong technology names.

Risk: Negative earnings (EPS -7.88) and thin trading volume increase volatility. The stock’s 52-week range (HK$198.00 to HK$879.00) shows large downside and upside swings. Investors should weigh execution risk, regulatory factors in China, and funding needs.

Trading strategy and price targets for 9678.HK stock

We frame near-term tactical levels and model-based targets. A conservative near-term price target is HK$400.00 on a successful retest of the 50-day average. Model-driven medium-term target aligns with Meyka’s monthly projection at HK$533.54.

Position sizing should reflect high volatility and an average daily volume below peers. Use stop-loss near HK$300.00 for tactical trades and reassess at quarterly reports or material product updates. For more detail see the Meyka AI stock page at Meyka AI stock page.

Final Thoughts

Key takeaways: 9678.HK stock trades at HK$344.80 pre-market on 19 Feb 2026 with light volume and mixed technicals. Valuation is stretched by negative EPS -7.88 and a trailing PE of -43.76, while sector peers show a positive PE environment. Meyka AI’s model projects a monthly price of HK$533.54, implying a model-based upside of 54.78% versus today’s price. We rate this a high-risk, growth-oriented idea where catalysts include product adoption in healthcare and improved earnings. Use disciplined risk management, with a tactical stop near HK$300.00 and a near-term target of HK$400.00, while the model-based projection supports a medium-term objective near HK$533.54. Forecasts are model-based projections and not guarantees. Meyka AI provides the analysis as an AI-powered market analysis platform and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.